Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by Takeda Pharmaceutical Company, Ltd. in connection with DEXILANT® (dexlansoprazole) delayed-release capsules, 30 mg and 60 mg. Impax filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic version of DEXILANT® with the U.S…
Acid Reflux / GERD News From Medical News Today Tags: Capsules, Challenge, confirms, DelayedRelease, DEXILANTR, Impax, Laboratories, Patent, Relating
This entry was posted on November 15, 2011 at 9:58 am and is filed under Acid Reflux/GERD. You can follow any responses to this entry through the RSS 2.0 feed.
